Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.76 |
| ▸ | GSTP1 | P09211 | 16/20 | 0.75 |
| ▸ | GSTM2 | P28161 | 16/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6833698 | 0.87 | IDO1 (0.78) | IDO1GSTP1GSTM2 | |
| SCHEMBL6831327 | 0.86 | IDO1 (0.76) | IDO1GSTP1GSTM2 | |
| SCHEMBL18895761 | 0.86 | IDO1 (0.76) | IDO1GSTP1GSTM2 | |
| SCHEMBL297980 | 0.86 | IDO1 (1.00) | IDO1GSTP1GSTM2 | |
| SCHEMBL297920 | 0.86 | IDO1 (1.00) | IDO1GSTP1GSTM2 | |
| SCHEMBL6831349 | 0.86 | IDO1 (0.76) | IDO1GSTP1GSTM2 | |
| SCHEMBL18895758 | 0.86 | IDO1 (0.76) | IDO1GSTP1GSTM2 | |
| SCHEMBL6836307 | 0.86 | GSTP1 (1.00) | IDO1GSTP1GSTM2 | |
| SCHEMBL18878890 | 0.85 | GSTP1 (0.77) | IDO1GSTP1GSTM2 | |
| SCHEMBL18895759 | 0.84 | GSTP1 (0.80) | IDO1GSTP1GSTM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796317-B2 | Use of 7-nitro-2,1,3-benzoxadiazole derivatives for anticancer therapy | Universita Degli Studi Di Roma “Tor Vergata” (IT) | 2014-08-05 | — | — | US | disclosed |
| US-20060247284-A1 | Use of 7-nitro-2,1,3 benzoxadiazole derivatives for anticancer therapy | UNIVERSITA DEGLI STUDI DI ROMA "TOR VERGATA" (IT) | 2006-11-02 | — | — | US | disclosed |
| EP-1615638-B1 | USE OF 7-NITRO-2,1,3 BENZOXADIAZOLE DERIVATIVES FOR ANTICANCER THERAPY | UNIV ROMA (IT) | 2006-09-27 | — | — | EP | disclosed |
| EP-1615638-A1 | USE OF 7-NITRO-2,1,3 BENZOXADIAZOLE DERIVATIVES FOR ANTICANCER THERAPY | Università degli Studi di Roma " Tor Vergata" (IT) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004093874-A1 | USE OF 7-NITRO-2,1,3 BENZOXADIAZOLE DERIVATIVES FOR ANTICANCER THERAPY | UNIVERSITA' DEGLI STUDI DI ROMA 'TOR VERGATA' (IT) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247284-A1 | Use of 7-nitro-2,1,3 benzoxadiazole derivatives for anticancer therapy | GSTK1, GSTP1, GSTM1 | IDO1 2872/4885GSTP1 2/4885GSTM2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.